Mobilization of Stem Cells With AMD3100 (Plerixafor) in Non-Hodgkin's Lymphoma Patients
Status:
Completed
Trial end date:
2007-12-01
Target enrollment:
Participant gender:
Summary
The purpose of this study is to determine whether the combination of AMD3100 (plerixafor) and
granulocyte colony-stimulating factor (G-CSF or generic name filgrastim) is better than G-CSF
alone to mobilize and collect the optimal number of stem cells in non-Hodgkin's lymphoma
patients for autologous transplantation.